Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer
| Autor: | Anssi Nikkola, Reetta Huttunen, Olli Limnell, Jussi Nikkola, Janne Aittoniemi, Juhani Sand, Irina Rinta-Kiikka, Johanna Laukkarinen, Anu Aronen, Isto Nordback |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Urinary system Gastroenterology Receptors Urokinase Plasminogen Activator 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pancreatic cancer Internal medicine medicine Humans Prospective Studies Creatinine business.industry Cancer medicine.disease Prognosis Pancreatic Neoplasms chemistry SuPAR ROC Curve 030220 oncology & carcinogenesis Area Under Curve Biomarker (medicine) Pancreatitis 030211 gastroenterology & hepatology business Plasminogen activator Biomarkers |
| Zdroj: | Scandinavian journal of gastroenterology. 56(1) |
| ISSN: | 1502-7708 |
| Popis: | Objectives SuPAR (soluble urokinase-type plasminogen activator receptor) is a biomarker reflecting the inflammatory state of the human body. Earlier studies suggest that urinary suPAR/creatinine ratio levels are elevated in chronic pancreatitis (CP), and that plasma suPAR (P-suPAR) level is elevated in pancreatic cancer (PC). Our aim was to study the levels of P-suPAR in CP in a long-term prospective follow-up setting to explore the possibility of distinguishing between PC and CP. Materials and methods Two patient groups were compared. The first group included 83 patients who were prospectively followed up after their first acute alcohol-induced pancreatitis (AAP) for median 7.0 (range 0.3-9.8) years. Twelve patients in this group developed CP during follow-up, and two patients were further excluded from the CP cohort. The second group consisted of 25 patients operated on for suspicion of pancreatic malignancy and final pathological diagnosis of PC. P-suPAR levels were measured and compared within and between these groups. Results P-suPAR levels remained low during follow-up despite the development of CP. P-suPAR was significantly higher in PC patients [median 3.7 (IQR 3.1-4.4) ng/mL] than in CP patients [2.6 (1.8-3.6) ng/mL]; p = .014. A cutoff value of 2.8 ng/mL resulted from a ROC curve with area under curve (AUC) of 0.79 (95% CI 0.61-0.97), p = .009 in differentiation between PC and CP with a sensitivity and a specificity of 88% and 70% respectively. Conclusion P-suPAR is higher in patients with PC than in patients with CP, and it could thus be used in differentiating between PC and CP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|